Sana Biotechnology, Inc.

NASDAQ:SANA

Biotechnology

Healthcare
$1.85 +1.23%

+$0.04 today

Market cap
$554.32M
Beta
2.16
P/E (TTM)
-3.5
EPS (TTM)
-$0.87
52W Low $2.58High $6.55

Volume 2.66M

Average 3.76M

SANA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Sana Biotechnology, Inc.NASDAQ: SANA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $47.21M (cash outflow) fell 4.4% year over year, behind the +16.0% change in trailing-twelve-month net income. Sequentially, it fell 19.7% from the prior quarter. Over 3 fiscal years it compounded at -3.2% a year.

Context

  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$156.26M (-36.0%) for the fiscal year ending Dec 2026, a slowdown from the -8.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$47.21M-19.7% QoQ
Last fiscal yearDec 2025
-$244.17M-8.5% YoY
LTMMar 2026
-$241.99M+16.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.4%-56.6%-52.2 pp
1 year-8.5%-36.0%-27.5 pp
3-year CAGR-3.2%-16.9%-13.6 pp
5-year CAGR-8.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(244.17M) USD
Year-over-year change
+8.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How SANA compares with its peers on the latest reported figures

  • SANA's LTM Mar 2026 net income of $241.99M is the 3rd largest of the 11 companies compared; the peer median is $118.85M.
  • Its year-over-year change of +16.0% is the 4th highest of 11, against a peer median of -16.4%.
  • Over three fiscal years its annual growth of -3.2% compares with a peer median of -19.2%.
SANA Competitors Peer median
Net Income for SANA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$500.92M -4.8%+3.1%757.9%
CRSPCRISPR Therapeutics AGLTM Sep 2026$456.14M -6.6%-3.6%1812.1%
SANASana Biotechnology, Inc.LTM Mar 2026$241.99M +16.0%-3.2%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$221.04M +23.7%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M -31.1%-16.9%—
FATEFate Therapeutics, Inc.LTM Mar 2026$129.91M -26.1%-21.5%2056.8%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$107.79M +391.1%-58.2%—
BEAMBeam Therapeutics Inc.LTM Jun 2026$85.43M -78.6%-34.8%54.7%
DTILPrecision BioSciences, Inc.LTM Mar 2026$43.6M +98.3%-25.7%96.7%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$9.47M -39.5%—40.9%
LEGNLegend Biotech CorporationLTM Sep 2026$2.81M -98.7%-12.6%0.2%
Peer median (excluding SANA) $118.85M-16.4%-19.2%96.7%

Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(355.93M)(269.48M)(283.26M)(266.76M)(244.17M)
Depreciation & Amortization11.07M15.63M24.56M17.39M12.75M
Deferred Income Tax00000
Stock-Based Compensation22.36M38.34M35.53M37.68M25.46M
Change in Working Capital9.8M7.54M18.61M(1.19M)(10.11M)
Accounts Receivables00000
Inventory00000
Accounts Payables(266K)1.06M1.03M1.38M(3.55M)
Other Working Capital10.07M6.48M17.58M(2.56M)(6.57M)
Other Non-Cash Items61.64M(82.08M)(49.03M)(10.28M)72.24M
Operating Cash Flow(251.05M)(290.05M)(253.58M)(223.15M)(143.83M)
Capital Expenditures(29.86M)(20.88M)(20.03M)(33.43M)(938K)
Acquisitions (Net)0(231.44K)(192.04K)01.43M
Purchases of Investments(491.39M)(78.69M)(157.74M)(226.06M)(87.29M)
Sales of Investments280.03M310.13M349.79M276.95M46.56M
Other Investing Activities(4.57M)231.44K192.04K17.45M0
Investing Cash Flow(245.8M)210.56M172.01M17.45M(40.24M)
Debt Repayment0007.74M(347K)
Common Stock Issued631.75M4.91M31.65M181M129.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00011.01M0
Financing Cash Flow631.75M4.91M31.65M199.75M128.73M
Effect of Forex Changes00000
Net Change in Cash134.9M(74.58M)(49.92M)(5.95M)(55.33M)
Free Cash Flow(280.92M)(310.93M)(273.61M)(256.58M)(144.77M)

Sana Biotechnology, Inc.

NASDAQ:SANA

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.